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Abstract 
Review on Peutz-Jeghers syndrome, with data on 
clinics, and the genes involved. 
Identity 
Other names 
Hamartomatous Intestinal Polyposis 
Polyps-and-Spots Syndrome 
Note 
Syndrome associating mucocutaneous melanotic 
pigmentation, intestinal polyposis, and an increased 
risk of cancers. 
Inheritance 
Autosomal dominant with a high penetrance; 
incidence rate of the disease ranges from 1 in 8,300 
to 1 in 200,000; 1/3 to 1/2 of cases due to de novo 
mutations. 
Clinics 
Phenotype and clinics 
Skin numerous brown or bleuish mucocutaneous 
macules (melanin spots), especially around the 
orifices (mouth, including the buccal mucosa, eyes, 
nostrils, anus, genitalia), and digits; the skin 
hyperpigmentation may disappear with age, in 
puberty and adulthood. Note: in patients with 
isolated mucocutaneous melanotic pigmentation 
(without polyps), the cancer risk is lower, and the 
genetic defect seems different. 
Gastrointestinal tract (GI tract): polyps of 
hamartomatous origin (with a characteristic 
arborization of nonstriated muscles) may be found in 
any portion of the GI tract with varying frequencies: 
from 95% to 15%: (small bowel, jejunum, ileum, 
large intestin, rectum, stomach, duodenum).  
Intussusception and bleeding are common 
symptoms, which may be cause of death. the age of 
onset is variable from the first year of life onwards 
(median age of onset 10-25 yrs); polyps have also 
been reported in other organs (renal pelvis, urinary 
bladder, ureters, lungs, nares, gallbladder). 
Neoplastic risk 
Tumors develop, with a relative risk of 10-20, and a 
cumulative risk of more than 90% between ages 15 
and 64 yrs (Giardiello et al.,2000).  
The mean interval between the diagnosis of PJS and 
the diagnosis of cancer is about 20 yrs (the mean age 
at the first cancer diagnosis about 41 yrs). The 
overall relative risk (RR) for cancer is greater in 
females than in males and greatest for 
gastrointestinal, pancreatic, and gynecologic-
cervical cancers (Resta et al.,2013). In particular, the 
specific RR is: 
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benign sex cord tumor with annular tubules in 
females or Sertoli cell tumors in males: 27 
lung: 17 
uterus: 16 
breast: 15.2 (comparable to that of BRCA1 / BRCA2 
mutations carriers - Hearle et al.,2006) 
Treatment 
Surveillance with endoscopic (GI tract) and 
gynecologic regular screenings, surgery when 
needed. 
Evolution 
Patients inherit mutations in one allele. The 
remaining allele is later inactivated generally by 
LOH or sometimes somatic mutation. This biallelic 
inactivation of STK11 leads to a loss of tumor 
suppressor activity, thereby promoting 
tumorigenesis. 
Prognosis 
The prognosis for individuals affected by PJS is thus 
mainly determined by the risk of malignancy. 
Although little information on prognosis is available, 
one report suggests that PJS-associated cancers are 
particularly aggressive (Spigelman et al.,1989). 
Several researches show that a diagnosis of PJS has 
great psychosocial impact, although the physical 
impact on the patient is not greater than that in the 
general population (Woo et al.,2009). 
Genes involved and 
proteins 
STK11 (LKB1) is the only gene in which mutations 
has been identified as causative of PJS, to date 
(Hemminki et al.,1998, Jenne et al.,1998). Evidence 
for genetic heterogeneity are described but no other 
locus has been clearly associated.  
One child with a PJS hamartoma show a 19q13.4 
translocation, however no pathogenic variants in 
candidate genes mapping to this breakpoint were 
identified (Hearle et al.,2004).  
Between 25 patients with PJS without STK11 
pathogenic mutations, one had a heterozygous 
pathogenic variant of MUTYH gene, common cause 
of autosomal recessive form of adenomatous 
polyposis (Alhopuro et al.,2008).  
Moreover Wang et colleagues identified 2 germline 
variants which are represented in all six PJS samples 
analyzed and are independent of STK11 mutation 
(Wang et al.,2014). 




A majority of PJS patients shows germline mutations 
in STK11 gene (around 80%-94%). However, the 
identification of germline mutations in other genes 
suggests a genetic heterogeneity of PJS, no definitely 
known to date. 
DNA/RNA 
Description 
9 coding exons, spanning 23 kb. (Additional non-
coding exons are described). The gene is transcribed 
in telomere to centromere direction. 
Transcription 
9 transcripts; 4 protein coding. 
Protein 
Description 
433 amino acids, 48.6 kDa; N-term with a nuclear 
localization domain and a putative cytoplasmic 
retention signal, a kinase domain, and a C-terminal 
CAAX box prenylation motif. 
Expression 
Ubiquitous, especially high expression in fetal liver 
and testis where it is required during spermiogenesis 
(Towler et al.,2008). 
Localisation 
Found in both the nucleus and the cytoplasm. 
Localization is thought to be dependent on 
interaction with proteins such as SMARCA4 
(BRG1), STK11IP (LIP1), STRADA, CAB39 
(MO25). 
Function 
Tumor suppressor serine/threonine-protein kinase 
that controls the activity of AMP-activated protein 
kinase (AMPK) family members, thereby playing a 
role in various processes such as cell metabolism, 
cell polarity, apoptosis and DNA damage response. 
Acts by phosphorylating the T-loop of AMPK 
family proteins, leading to promote their activity: 
phosphorylates PRKAA1 , PRKAA2 , BRSK1 , 
BRSK2 , MARK1 , MARK2 , MARK3 , MARK4 , 
NUAK1 , NUAK2 , SIK1 , SIK2 , SIK3 and SNRK 
but not MELK. Also phosphorylates non-AMPK 
family proteins such as STRADA and possibly 
p53/TP53. Acts as a key upstream regulator of 
AMPK by mediating phosphorylation and activation 
of AMPK catalytic subunits PRKAA1 and 
PRKAA2: it thereby regulates inhibition of signaling 
pathways that promote cell growth and proliferation 
when energy levels are low, glucose homeostasis in 
liver, activation of autophagy when cells undergo 
nutrient deprivation, B-cell differentiation in the 
germinal center in response to DNA damage. Also 
acts as a regulator of cellular polarity by remodeling 
the actin cytoskeleton. Required for cortical neurons 
polarization by mediating phosphorylation and 
activation of BRSK1 and BRSK2, leading to axon 
initiation and specification. Involved in DNA 
damage response: interacts with p53/TP53 and 
recruited to the CDKN1A/WAF1 promoter to 
participate in transcription activation. Able to 
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phosphorylate p53/TP53; the relevance of such 
result in vivo is however unclear and 
phosphorylation may be indirect and mediated by 
downstream STK11/LKB1 kinase NUAK1 Also acts 
as a mediator p53/TP53-dependent apoptosis via 
interaction with p53/TP53: translocates to 
mitochondrion during apoptosis and regulates 
p53/TP53-dependent apoptosis pathways (Karuman 
et al.,2001; Baas et al.,2003; Boudeau et al.,2003; 
Baas et al.,2004; Lizcano et al.,2004; Jaleel et 
al.,2005; Zeng et al.,2006; Hou et al.,2011). 
Homology 
Orthologs found in several species and include: 
Xenopus laevis egg and embryonic kinase 
1(XEEK1), Caenorhabditis elegans partitioning 




Around 200 pathogenic mutations of STK11 gene 
has been reported to date, including missense, 
nonsense, splice site variants, small deletions, small 
insertions, small indels, large deletions, large 
insertions and complex rearrangements. Between 
them more than 90% are associated with PJS. In 
addition are described: one individual with a 
nonsense variant and diagnosis of gonadotropin-
independent precocious puberty and one patient with 
a large insertion and diagnosis of juvenile polyposis 
syndrome. 
Somatic 
Many of the polyps that develop in PJS show loss of 
heterozygosity or second somatic mutation of 
SKT11 gene. Somatic mutations rarely occur in 
sporadic tumors. However, somatic mutations of 
STK11 gene can be frequent revealed in lung 
adenocarcinoma (Matsumoto et al.,2007). 
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